CryoLife heart valve
This article was originally published in The Gray Sheet
Atlanta biomaterials, medical device and tissue processing firm receives 510(k) clearance Feb. 7 for its CryoValve SG pulmonary human heart valve. The valve is manufactured from donated human tissue using the firm's proprietary SynerGraft technology, which removes the tissue cells to leave only a collagen scaffold, and could lower the risk of immune response and subsequent tissue rejection, according to FDA. The product shows particular promise for children with congenital heart defects, the company says. CryoLife is planning a post-clearance study to demonstrate the SynerGraft process' potential and long-term benefits and will begin shipping the valve by April
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.